Sign in
4

Changes in Ownership

Denali Therapeutics Inc. Filed Acc 0001714899-24-000206

President and CEO sold 40,000 shares at $27.69 ($1,107,600)

  • President and CEO acquired 40,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Watts Ryan J. · President and CEO

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2024-10-18 Exercise or conversion : show line 1 in the form 10b5-1 +40,000 $0.68 $27,200 275,807 D
2024-10-18 Sale : show line 2 in the form 10b5-1 −40,000 $27.69 $1,107,600 235,807 D
Open-market sales · 40,000 sh · avg $27.69 · $1,107,600

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2024-10-18 Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) −40,000 1,078,091 D
Loading xslF345X05/wk-form4_1729629050.xml…